Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Eric Viaud"'
Autor:
Antoine Ferry, Felix Bock, Frank Wilhelm, Daniel Böhringer, Tobias Meyer-ter-Vehn, Björn Bachmann, Beatrice E. Frueh, Salman Al Mahmood, François Majo, Uwe Pleyer, Daniel Meller, Bernard Geudelin, Pavla Kadlecová, Gerd Geerling, Eric Viaud, Thomas Reinhard, Claus Cursiefen, Berthold Seitz, Michel Lévy, Sylvie Colin, Eric Thorin
Publikováno v:
Ophthalmology. 121(9):1683-1692
Objective Eye drops of aganirsen, an antisense oligonucleotide preventing insulin receptor substrate-1 expression, inhibited corneal neovascularization in a previous dose-finding phase II study. We aimed to confirm these results in a phase III study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::920620f1aa12f576a85ca343ddac7023
Autor:
Eric Viaud, Claus Cursiefen
Publikováno v:
Ophthalmology. 122:e28-e29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7d4686ba2667ffa3b66d649ef0f1914
https://doi.org/10.1016/j.ophtha.2014.10.018
https://doi.org/10.1016/j.ophtha.2014.10.018
Autor:
Salman Al-Mahmood, Stéphanie Lamoureux, Robin J Goody, Frank Cloutier, Patricia Udaondo, Eric Thorin, Jean-Pascal Conduzorgues, Amel Hadri, Sylvie Colin, Sylvain Chemtob, Eric Viaud, Claus Cursiefen, Antoine Ferry, Matthew Lawrence
Publikováno v:
Investigative ophthalmologyvisual science. 53(3)
PURPOSE. Aganirsen, an antisense oligonucleotide inhibiting insulin receptor substrate (IRS)-1 expression, has been shown to promote the regression of pathologic corneal neovascularization in patients. In this study, the authors aimed to demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e9e433e7a0071b63bd4d5ad10be94df
https://pubmed.ncbi.nlm.nih.gov/22323484
https://pubmed.ncbi.nlm.nih.gov/22323484
Publikováno v:
European Ophthalmic Review. :190
Angiogenesis is a complex process that is vital to health but is also a driving factor behind a broad range of malignant, ischaemic, inflammatory, infectious and immune disorders. For optimal efficacy and safety, therapies aimed at preventing angioge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9dec95d37cdec6e00aa5f06f20f6e0f
https://doi.org/10.17925/eor.2012.06.03.190
https://doi.org/10.17925/eor.2012.06.03.190